Objective: We evaluated what prenatal genetic counselor's (GCs) practices, attitudes, and barriers are in regards to prenatal microarray since the publication of the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) guidelines for microarray use.
recommending CMA as the first-line test when a prenatal ultrasound shows one or more major fetal abnormalities. 2 These guidelines also recommend CMA as the preferred genetic test to help identify the cause of fetal demise and stillbirths, and that CMA should be offered to any patient undergoing diagnostic testing. 2 This was further corroborated by the updated 2016 ACOG and SMFM practice bulletin, which currently recommends CMA as the primary test, replacing karyotype, for patients with fetal structural abnormalities and stillbirths. 3 Limitations of CMA include the possibility of detecting variants of uncertain significance (VUS), which are estimated to occur at a rate of 1.6%-2.1%, as well as limited insurance coverage, especially in the absence of ultrasound abnormalities or other high-risk factors. [4] [5] [6] [7] [8] Appropriate pretest and post-test genetic counseling, with a thorough and thoughtful discussion of the benefits and limitations, is warranted for patients who choose to have a prenatal microarray performed. ACOG recommends that certain points should be discussed with the patients prior to undergoing CMA. 3 While this discussion and ordering of prenatal CMA can be done by various healthcare providers, genetic counselors (GCs) are a subgroup of health professionals who are uniquely trained in counseling regarding the benefits, limitations, and risks associated with prenatal screening and testing options.
GCs frequently facilitate the selection of prenatal tests, interpret and disclose these results, and facilitate decision making and coordination of care following the results. While genetic counselors play an integral role, studies regarding the experiences and attitudes of genetic counselors are limited.
A 2012 survey of 160 prenatal GCs practicing in North America
showed that the majority (73%) of respondents found prenatal microarray to be a useful tool, 84% presented it to patients as a prenatal diagnostic option, and 69% ordered it at least once. Reported challenges included financial issues and ethical concerns, as well as the difficulty of interpreting uncertain results and explaining these complex results to patients. 9 Another study of 193 prenatal GCs found that 59% of counselors would be comfortable providing genetic counseling about prenatal microarray, and 43% would be comfortable helping a patient make a decision about pregnancy termination in the presence of an uncertain microarray result. 10 What does this study add?
• This is the first study to show how prenatal CMA is being utilized after publication of the ACOG and the SMFM committee opinion and shows that majority of prenatal counselors are following guidelines.
• Prenatal counselors believe that benefits of CMA outweigh the risks but are less likely to offer CMA for all routine indications.
• Financial concerns do not appear to be a large barrier to offering CMA, however, patient-specific concerns, difficulty in interpreting the results, and lack of data remain as barriers. 
| Demographics
A complete list of participant's demographics is summarized in Table 1 . 
| Knowledge and beliefs
A complete list of participants reported knowledge and beliefs is summarized in Table 2 . Participants were asked to describe their current level of knowledge regarding prenatal CMA, with 163 of 192 (85%)
reporting they felt they were either an expert and could teach others, or that they were comfortable ordering the test without further education, and 166 (86%) reported to be current with clinical guidelines for the use of prenatal CMA. A little over half, 99 (52%), agreed that CMA should be offered to all patients regardless of indication, and 123 (64%) agreed that the benefits of CMA in its current form outweigh harms.
| Incorporation into practice
Of the 192 respondents 183 (95%) reported that they have incorporated prenatal CMA into their practice by offering the test as an option to patients. In order to evaluate their current utilization and practices, we put forward sample indications, modeled on standard prenatal indications and ACOG guidelines, and asked participants how frequently they offer prenatal CMA given that specific indication by responding as "mostly or always," "sometimes," and "rarely or never." Results are summarized in Figure 1 . The sample indication of "all patients undergoing genetic counseling" was intended to capture indications such as, for example, family history of spina bifida or exposure to teratogens, all which may be indications for counseling but not necessarily warrant an invasive procedure or an array. "All patients undergoing invasive testing, regardless of indication" was intended to capture patients who may have invasive testing performed for another indication, which may not be associated with an increased risk for chromosome abnormalities or CNVs, such as parents being cystic fibrosis carriers.
Of the 183 participants who incorporated CMA into their practice, 174 (95%) reported that they "mostly" or "always" offer CMA to patients with a structural fetal anomaly and none of the participants reported to "never" or "rarely" offer CMA when an anomaly is present.
Eighty seven percent (160/183) of the participants reported to "mostly" or "always" offer CMA to patients presenting with a fetal demise or stillbirth, and 130 (71%) reported to "mostly" or "always"
offer CMA to their patients undergoing invasive testing.
The participants that were offering CMA to patients undergoing invasive testing were significantly more likely to report feeling comfortable in their knowledge of CMA and did not need further education (P = 0.011). Participants who reported to "rarely" or "never"
offer CMA to patients undergoing invasive testing, 37/183 (20%),
were significantly more likely to report that the difficulty of interpreting results was influential in not offering the test (P = 0.009) and were significantly more likely to disagree that CMA should be offered to all patients (P < 0.001).
In general, participants reported "mostly" or "always" offering prenatal CMA for all of the indications provided with the exception of two indications: advanced maternal age (AMA) and all patients undergoing prenatal genetic counseling. For AMA, approximately 82 of 183 (45%) of participants reported to "rarely" or "never" offer CMA and 81 (44%) reported to "mostly" or "always" offer CMA.
Those that "mostly" or "always" offer the test for AMA were significantly more likely to report being comfortable with their knowledge of CMA (P = 0.001). Those who were not offering CMA for AMA were significantly more likely to report desiring more education (P = 0.001).
When asked if CMA was offered to all patients undergoing prenatal genetic counseling, 121 of 183 (66%) reported "rarely" or "never"
offering CMA, while 38 (21%) said they "mostly" or "always" offered CMA. Of the participants who are not offering CMA for all patients undergoing genetic counseling, they were significantly more likely to report that patient-specific concerns (P = 0.047) and difficulty in interpreting the results (P = 0.009) influenced this decision. Of the participants who are not offering CMA for all patients undergoing genetic counseling and for patients who are AMA, this group was significantly more likely to disagree that prenatal CMA should be offered to all patients regardless of indication (P < 0.001 and P < 0.001, respectively).
The participants who reported "never" or "rarely" offering CMA to patients with nonstructural abnormalities, a family history of microdeletion and microduplication syndromes, positive screen for aneuploidy, and patients who want all information possible were significantly more likely to report that the lack of data regarding yield/utility influenced this decision (P = 0.001; P = 0.035; P = 0.004, and P = 0.001, respectively). Frequency of use of CMA was compared with other demographic information provided by the participants, and no other statistically significant trends were encountered.
| Barriers
Several reasons for not offering CMA were reported by the participants, including patient specific concerns, 93 of 183 (51%); difficulty of interpreting results/lack of data, 71 (39%); financial concerns, 68
(37%); and time constraints 40 (22%). Barriers were compared with 
| Laboratory affiliation
Of the GCs who reported working for an institute or entity that performs prenatal CMA (n = 49), 96% (n = 47) offered CMA in their clinical practice and were more likely to feel comfortable in their knowledge of CMA 94% (n = 44/47) than their fellow participants 84% (n = 114/136). When it came to offering CMA, these GCs offered it more often to patients undergoing diagnostic testing 74% (n = 35) and were more likely to report that financial concerns (68% . These were all found to be statistically significant (P < 0.05).
| Pretest and test ordering practices
Participants who have incorporated CMA into clinical practice were asked how frequently they discussed certain points during pretest counseling. These results are summarized in Figure 3 . The points that were "mostly" or "always" discussed by participants include: CMA can yield a pathogenic or abnormal result Approximately, half of participants reported that they "rarely" or FIGURE 2 Factors that play a role when prenatal CMA is not offered to the patient. Responses gathered through survey, with total number of responses of n = 183
FIGURE 3
Frequency of pretest counseling discussion points for prenatal CMA. Responses gathered through survey, with total number of responses of n = 183. Responses were grouped together for those who most or always offer CMA given a specific indication and those that rarely or never offer CMA given a specific indication
FIGURE 4
Resources used to stay current on information about prenatal CMA. Responses gathered through survey, with total number of respondents of n = 183. Respondents were asked to choose all that apply so total number of responses is greater than 183
"never" discuss that results may indicate an adult onset disorder (88
[48%]). This was compared with demographic information provided by the participants and no statistically significant trends were encountered.
Of the participants who incorporated CMA into practice, 101 of 183 (55%) reported ordering expanded arrays 117/183 (64%) and 60/183 (33%) reported ordering targeted arrays. Participants also reported ordering SNP arrays 104/183 (57%) more frequently than other types of arrays.
Of the 183 participants, 21 (15%) reported that they, or their institution, participated in data sharing, 84 (46%) did not, and 72 (39%) were unsure. Those who reported data sharing were significantly more likely to work for an academic institution (P = 0.046).
However, working at a fetal center did not make a GC more likely to participate in data sharing (P > 0.05) and neither did working for an institution that performs CMA (P > 0.05).
| Resources
Participants were asked what resources they use to stay current on information regarding prenatal CMA. Of the 183 participants, 176 (96%) reported using the guidelines or practice bulletins from professional organizations and 160 (87%) reported using information gathered at national or scientific meetings. In the free response section, several participants stated that expert knowledge and recommendations of laboratory genetic counselors and discussions with their colleagues were important resources used to stay current on information.
| DISCUSSION
This cross-sectional study of practicing prenatal genetic counselors shows that nearly all prenatal counselors (95%) surveyed have incorporated prenatal CMA into their clinical practice by offering it to their patients, and the majority (83%) report feeling very comfortable in their current knowledge of prenatal CMA, without desiring further education. This is higher than the previously reported surveys. While the increase in utilization of the test is likely driven by the availability of professional guidelines, the increase of comfort level is likely a reflection of more peer-reviewed literature showing the majority of variants of uncertain significance are reclassified and that CMA has a high yield in the prenatal setting, particularly in the presence of structural abnormalities. 1, 7, [11] [12] [13] [14] Other factors that may contribute to increased comfort levels and utilization were explored, such as years of experience and demographic information regarding work setting/number of patients seen, but no significant correlations were uncovered. In the current study, we are only able to generalize that counselors appear to be more comfortable given that the vast majority are offering the testing, however, future studies should consider exploring possible counselor and patient-specific factors impacting prenatal CMA uptake specifically looking at GCs who started offered prenatal genetic counseling and prenatal CMA prior to and after the guideline publications to better understand what influence the guidelines had on their attitudes, utilization, and comfort levels. The vast majority (95%) of genetic counselors in this study are offering prenatal CMA to patient's whose fetus has been identified with a structural anomaly, 87% are offering CMA in the presence of stillbirth or fetal demise, and 71% are offering CMA to all patients undergoing invasive testing. Additionally, most participants are reviewing suggested pretest counseling discussion points with the patients indicating that prenatal counselors were practicing in concordance with current ACOG and SMFM guidelines even before these discussion points were explicitly delineated. by the information provided. [18] [19] [20] [21] Our study also did not define if the patient concerns are perceived to be barriers by the counselor based on the interaction with the patient or concerns verbalized to the counselor directly by the patient, or both. We did receive some comments from the respondents that stated when a patient is up front about not wanting to discuss invasive testing options, the counselors do not offer CMA. This may also fall into "patient-specific concerns,"
although we cannot confirm that that is how the participant would define this response.
Difficulty of interpreting results and lack of data were the second most common barriers cited when CMA is not offered, Past studies largely reported on financial concerns as a major barrier 9 to ordering prenatal CMA. However, in our study, financial issues were not a frequently cited barrier from our participants.
Increasing coverage of CMA testing by commercial insurance pro- for mitigating patient and provider concerns and anxiety. We understand and appreciate the intricacy of these issues and that developing recommendations will be challenging and complex. However, we must have the foresight that genetics is a rapidly evolving field. We must address the concerns that arise within our community as we continue to make medical advances.
There were several limitations to this study. This survey was distributed via email to the entire NSGC membership listserv and the exact response rate could not be calculated. Additionally, GCs who either are not members of NSGC, or those who declined to receive student surveys were not represented in our results. With any study, there is the inherit selection bias that those who take part may have an affinity for this subject matter or have very strong opinions regarding CMA.
Additionally, the results and subsequent conclusions we drew from this study may have been skewed by the overall lack of experience of our participants. The study was not based on validated measures and the questions may have been misinterpreted by the participants.
| CONCLUSION
Overall, the study demonstrates that prenatal GCs, despite practicing in many different settings and with different years of experience, appropriately utilize CMA and follow professional guidelines.
Professional guidelines and published data on utility of prenatal CMA for indications, such as abnormal ultrasound findings, appear to have lessened some of the concerns previously cited by GCs.
There is still a significant lack of data on utility of CMA for routine prenatal indications and for all pregnant patients. Genetic counselors continue to cite difficulty interpreting VUS results and patient-related concerns, such as anxiety, as barriers to offering CMA.
